Apotex Company Profile

✉ Email this page to a colleague

APOTEX has three hundred and ten approved drugs.

There is one US patent protecting APOTEX drugs. There are fifteen tentative approvals on APOTEX drugs.

There is one patent family member on APOTEX drugs in one country and eight hundred and three supplementary protection certificates in eighteen countries.

International Patents:	1
US Patents:	1
Tradenames:	231
Ingredients:	223
NDAs:	310
Patent Litigation for Apotex:	See patent lawsuits for Apotex
PTAB Cases with Apotex as petitioner:	See PTAB cases with Apotex as petitioner

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Apotex	CYCLOBENZAPRINE HYDROCHLORIDE	cyclobenzaprine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206703-001	Jul 24, 2018		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Apotex Inc	ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE	ondansetron hydrochloride	INJECTABLE;INJECTION	077343-001	Dec 26, 2006		DISCN	No	No		⤷ Try a Trial				⤷ Try a Trial
Apotex	FLUPHENAZINE HYDROCHLORIDE	fluphenazine hydrochloride	TABLET;ORAL	216649-002	Jul 15, 2022	AB	RX	No	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Apotex	PAXIL CR	paroxetine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	020936-003	Dec 6, 2000	6,121,291*PED	⤷ Try a Trial
Apotex	PAXIL	paroxetine hydrochloride	TABLET;ORAL	020031-003	Dec 29, 1992	4,721,723*PED	⤷ Try a Trial
Apotex	PAXIL	paroxetine hydrochloride	CAPSULE;ORAL	020885-001	Oct 9, 1998	6,172,233*PED	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	25 mg	➤ Subscribe	2005-09-09
➤ Subscribe	Oral Suspension	10 mg/5 mL	➤ Subscribe	2005-02-10
➤ Subscribe	Extended-release Tablets	37.5 mg	➤ Subscribe	2009-05-19
➤ Subscribe	Delayed-release Tablets	20 mg	➤ Subscribe	2015-06-03

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2017002030	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0763039	PA2008009	Lithuania	⤷ Try a Trial	PRODUCT NAME: TEMSIROLIMUSUM; REG. NO/DATE: EU/1/07/424/001 20071119
3808743	2022C/531	Belgium	⤷ Try a Trial	PRODUCT NAME: EEN COMBINATIE VAN RILPIVIRINE OF EEN FARMACEUTISCH AANVAARDBAAR ADDITIEZOUT VAN RILPIVIRINE, EN EMTRICITABINE; AUTHORISATION NUMBER AND DATE: EU/1/11/737/001-002 20111128
0648494	24/2001	Austria	⤷ Try a Trial	PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.